{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T18:21:41Z","timestamp":1763058101706,"version":"3.41.2"},"reference-count":0,"publisher":"AVES YAYINCILIK A.\u015e.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["EJR"],"abstract":"<jats:p>Abstract\n\t\u00a0\n\n\tObjective: Endocan is a marker for vascular pathogenesis and important mediator of angiogenesis that strongly associates with inflammation and vascular diseases. Growing evidence suggest that inflammatory cytokine tumor necrosis factor (TNF-alpha) plays a role in its regulation and secretion, whereas TNF-alpha inhibitors may have the opposite influence. The aim of this research is to investigate the association between serum endocan and anti-TNF-alpha drug treatment in patients with ankylosing spondylitis (AS).\n\n\t\n\n\t\u00a0\n\n\tMethods: Serum endocan levels were analyzed in 42 patients with AS under anti-TNF-alpha usage. Control group consisted of 37 patients with AS who are not receiving anti-TNF drugs. Endocan is analyzed using ESM-1 ELISA kits. The blood glucose and lipid measurements of patients were also assessed.\n\n\t\n\n\t\u00a0\n\n\tResults: There was no significant change in serum endocan levels among groups. The total cholesterol, triglyceride, and LDL-C levels were higher in patients receiving anti-TNF-alpha; however, differences were not significant. There was no significant correlation between serum endocan levels and blood lipid measurements.\n\n\t\n\n\t\u00a0\n\n\tConclusion: Anti-TNF-alpha treatment does not affect serum endocan levels in patients with AS. This research has been first to evaluate the relationship between serum endocan and anti-TNF-alpha therapy in AS. Future studies are necessary to verify the exact role of anti-TNF-alpha therapy on serum endocan levels in patients with AS.\n\n\t\n\n\t\u00a0\n\n\tCite this article as: Kaday\u0131f\u00e7\u0131 FZ, Gezmen Karada\u011f M. The relationship of serum endocan levels and anti-TNF-alpha therapy in patients with ankylosing spondylitis. Eur J Rheumatol 2018; 5: 1-4.\n<\/jats:p>","DOI":"10.5152\/eurjrheum.2017.17287","type":"journal-article","created":{"date-parts":[[2017,11,17]],"date-time":"2017-11-17T07:47:05Z","timestamp":1510904825000},"page":"1-4","source":"Crossref","is-referenced-by-count":4,"title":["The relationship of serum endocan levels and  anti-TNF-alpha therapy in patients with ankylosing spondylitis"],"prefix":"10.5152","volume":"5","author":[{"given":"Makbule","family":"Gezmen Karada\u011f","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatma Zehra","family":"Kaday\u0131f\u00e7\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3111","published-online":{"date-parts":[[2019,9,3]]},"container-title":["European Journal of Rheumatology"],"original-title":[],"link":[{"URL":"https:\/\/www.eurjrheumatol.org\/index.php\/pub\/article\/download\/221\/221","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T07:26:47Z","timestamp":1753774007000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurjrheumatol.org\/index.php\/pub\/article\/view\/221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,3]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,9,3]]}},"URL":"https:\/\/doi.org\/10.5152\/eurjrheum.2017.17287","relation":{},"ISSN":["2148-4279"],"issn-type":[{"type":"electronic","value":"2148-4279"}],"subject":[],"published":{"date-parts":[[2019,9,3]]}}}